First person treated with cell-rejuvenating gene therapy for glaucoma

Life Biosciences on Monday announced that the first participant has been dosed in its Phase 1 clinical trial of ER-100, a gene therapy designed to reverse cellular aging in patients with vision loss — marking the first time partial epigenetic reprogramming has been tested in a human.globenewswire+1

The Boston-based biotechnology company, co-founded by Harvard Medical School biologist David Sinclair, is testing whether delivering three transcription factors — OCT4, SOX2, and KLF4, collectively known as OSK — can rejuvenate deteriorating retinal ganglion cells in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).nature+1

How the Therapy Works

ER-100 uses viral vectors to deliver genetic material directly into retinal cells. A second viral vector, activated by the antibiotic doxycycline, acts as a safety switch: when patients take a doxycycline pill, the therapy turns on; when they stop, it turns off. Participants will take doxycycline for eight weeks alongside a steroid to reduce inflammation.nad

The approach aims to reset epigenetic patterns — the chemical tags on DNA that accumulate with age — to a more youthful state, restoring function in damaged neurons that are not normally capable of regeneration. Life Biosciences reported in 2024 that the therapy restored visual function in a primate model of NAION.linkedin+3

Safety Questions Linger

The trial will primarily assess safety and tolerability, a lingering concern in the reprogramming field. The technique uses three of the four Yamanaka factors that, in laboratory settings, can push adult cells all the way back to a stem-cell-like state. The goal is to nudge cells back only partway — enough to rejuvenate without causing them to lose their specialized identity. Some scientists have cautioned that reprogramming gone awry could trigger uncontrolled cellular growth, a risk observed in earlier mouse studies.nature+1

A Landmark for the Longevity Field

The FDA cleared Life Biosciences' Investigational New Drug application on January 15, 2026, making ER-100 the first cellular rejuvenation therapy using epigenetic reprogramming to enter human trials. The company raised $80 million in Series D financing in April 2026 to fund the trial's completion and advance its broader platform into other tissue types, bringing total funding to nearly $240 million.lifebiosciences+3

The trial will enroll up to six glaucoma patients at two dose levels before establishing a dose to test in up to six NAION patients, and is being conducted at Harvard-affiliated Massachusetts Eye and Ear in Boston.nad+1

"The goal is to restore vision to some level and prevent further vision loss," Life Biosciences CEO Jerry McLaughlin said when the FDA clearance was announced earlier this year.nad